Assess Fibrin in Brains With AD/ADRD

Recruiting Phase 1 Phase 2 Interventional Study
Alzheimer Disease Dementia of Alzheimer Type
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
55 – 90
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Diagnostic
Participants needed
30 (estimated)
Sponsor
Massachusetts General Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age between 55 and 90 years * Ability to provide informed consent * Specific to healthy volunteers: no history of ADRD * Specific to ADRD subjects: clinical diagnosis of AD - either amnestic or atypical, clinical severity ranging from MCI to moderate dementia (CDR 0.5-2.0), MM…
Contacts

Ciprian Catana, MD, PhD

617-643-4885

ccatana@mgh.harvard.edu

CONTACT